Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines, Meeting Report, 19-21 February 2001, Chulalongkorn University, Bangkok, Thailand - Health Economics and Drugs Series No. 011
(2002; 67 pages) View the PDF document
Table of Contents
Open this folder and view contents1. Introduction
View the document2. Highlights of opening address of Dr Supachai Panitchpakdi
Open this folder and view contents3. 1Globalization, TRIPS and Access to Pharmaceuticals
View the document4. Further Reading
View the document5. Template of selected model indicators for studying the impact of globalization and TRIPS on access to medicines
Close this folder6. Selected indicators for studying the impact of globalization and TRIPS on access to medicines
View the documentRespondent data
Close this folderContents
View the documentI. Definitions used in the template**
View the documentII. Trends in total pharmaceutical consumption
View the documentIII. Health care coverage
View the documentIV. Structure of public and private pharmaceutical prices
View the documentV. Regulations relating to intellectual property rights protection and marketing authorization
View the documentVI. Prices of pharmaceutical products
View the documentVII. Market share of domestic and foreign firms
View the documentVIII. Regulation of pharmaceutical consumption - A stakeholder analysis
View the document7. The Collaborating Centres
 

VI. Prices of pharmaceutical products

Production

1. Who sets the prices of patented pharmaceutical products?

 

a) Market forces

Yes/No

 

b) Regulation

Yes/No

 

c) Other (please specify)

Yes/No

2. Who sets the prices of generic pharmaceuticals?

 

a) Market forces

Yes/No

 

b) Regulation

Yes/No

 

c) Other (please specify)

Yes/No

3. Is the process of drug registration linked to the pricing procedure?

 

Yes/No

4. Are the prices of pharmaceutical products regulated?

 

Yes/No

If the prices of pharmaceuticals are regulated with what method?

a) International price comparisons
b) Negotiation between manufacturers and national authorities
c) Regulating return on capital
d) Price-volume agreements
e) Price indicated in tender submitted to Ministry of Health
f) Do not know.

5. Is there a clearly defined state controlled mechanism to monitor the implementation of price controls?

Yes/No

a) If Yes, please check all that apply

(i)

Duty on imported raw materials

____________

(ii)

Duty on imported finished products

____________

(iii)

Maximum wholesale mark up

____________

(iv)

Maximum retail mark up

____________

(v)

Maximum retail price

____________

(vi)

No pricing policy/regulation

____________

Price indicators

1. Public and private prices of branded pharmaceuticals

Table G: Average annual public sector prices per standard dose of drugs (original brand)

Product and dosage*

1998

1999

2000

2001

2002

2003

Erythromycin** (250 mg)

           

Ciprofloxacin*** (250 mg)

           

Rifampicin (150 - 300 mg)

           

Doxycycline*** (100 mg)

           

Cyclophosphamide (25 mg)

           

Hydrochlorothiazide**** (25 mg)

           

Atenolol (50-100 mg)

           

Salbutamol***** (Inh. 100:g)

           

Candesartan (4 mg)

           

Celecoxib 200 mg)

           

Orlistat 120 mg)

           

Sildenafil (50 mg)

           

Olanzapine (10 mg)

           

Levofloxacin (500 mg)

           

Atorvastatin (10 mg)

           

Montelukast (10 mg)

           

Esomeprazol (20 mg)

           

Fluconazole (50 mg)

           

Zidovudine (300 mg)

           

Nevirapine (200 mg)

           

Azithromyci 500 mg

           

Didanosine (ddI) 150 mg

           

Indinavir 200 mg

           

Lamivudine 150 mg

           

Ofloxacin 200 mg

           

Lamivudine + Zidovudine 150 mg + 300 mg

           

Zidovudine + Lamivudine + Abacavir 300 mg + 150 mg + 300mg #

           

* If not indicated, pharmaceutical dosage forms are tablets. Divide the price of the pack by the number of doses (e.g. tablets) in order to give the price per dose

** stearate/ethylsuccinate

*** HCl

**** 50 mg (if 25 mg not available)

***** As sulphate

# If available as a fixed-dose combination.

Table H: Average annual private sector prices per standard dose (original brand)

Product and dosage*

1998

1999

2000

2001

2002

2003

Erythromycin** (250 mg)

           

Ciprofloxacin*** (250 mg)

           

Rifampicin (150-300 mg)

           

Doxycycline*** (100 mg)

           

Cyclophosphamide (25 mg)

           

Hydrochlorothiazide**** (25 mg)

           

Atenolol (50-100 mg)

           

Salbutamol***** (Inh. 100:g)

           

Candesartan (4 mg)

           

Celecoxib (200 mg)

           

Orlistat (120 mg)

           

Sildenafil (50 mg)

           

Olanzapine (10 mg)

           

Levofloxacin (500 mg)

           

Atorvastatin (10 mg)

           

Montelukast (10 mg)

           

Esomeprazol (20 mg)

           

Fluconazole 50 mg

           

Zidovudine 300 mg

           

Nevirapine 200 mg

           

Azithromycin 500 mg

           

Didanosine (ddI) 150 mg

           

Indinavir 200 mg

           

Lamivudine 150 mg

           

Ofloxacin 200 mg

           

Lamivudine + zidovudine 150 mg + 300 mg

           

Zidovudine + Lamivudine + Abacavir 300 mg + 150 mg + 300mg #

           

* If not indicated, pharmaceutical dosage form are tablets.
** stearate/ethylsuccinate
*** HCl
**** 50 mg (if 25 mg not available)
***** As sulphate
# If available as a fixed-dose combination.

Table I: Average annual public sector prices per standard dose (generic equivalents)

 

Number of generic equivalents on the market

1998

1999

2000

2001

2002

2003

   

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Product and dosage*

                                     

Erythromycin** (250 mg)

                                     

Ciprofloxacin*** (250 mg)

                                     

Rifampicin (150 - 300 mg)

                                     

Doxycycline*** (100 mg)

                                     

Cyclophosphamide (25 mg)

                                     

Hydrochlorothiazide **** (25 mg)

                                     

Atenolol (50 - 100 mg)

                                     

Salbutamol***** Inh. 100:g

                                     

Candesartan (4 mg)

                                     

Celecoxib (200 mg)

                                     

Orlistat (120 mg)

                                     

Sildenafil (50 mg)

                                     

Olanzapine (10 mg)

                                     

Levofloxacin (500 mg)

                                     

Atorvastatin (10 mg)

                                     

Montelukast (10 mg)

                                     

Esomeprazol (20 mg)

                                     

Fluconazole (50 mg)

                                     

Zidovudine (300 mg)

                                     

Nevirapine (200 mg)

                                     

Azithromycin (500 mg)

                                     

Didanosine (ddI) (150 mg)

                                     

Indinavir (200 mg)

                                     

Lamivudine (150 mg)

                                     

Ofloxacin (200 mg)

                                     

Lamivudine + Zidovudine (150 mg + 300 mg)

                                     

Zidovudine + Lamivudine + Abacavir (300 mg + 150 mg + 300mg) #

                                     

* If not indicated, pharmaceutical dosage forms are tablets.
** stearate/ethylsuccinate
*** HCl
**** 50 mg (if 25 mg not available)
***** As sulphate
# If available as a fixed-dose combination.

Table J: Average annual private sector prices per standard dose (generic equivalents)

 

Number of generic equivalents on the market

1998

1999

2000

2001

2002

2003

   

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Ave

Max

Min

Product and dosage*

                                     

Erythromycin** (250 mg)

                                     

Ciprofloxacin*** (250 mg)

                                     

Rifampicin (150 - 300 mg)

                                     

Doxycycline*** (100 mg)

                                     

Cyclophosphamide (25 mg)

                                     

Hydrochlorothiazide **** (25 mg)

                                     

Atenolol (50 - 100 mg)

                                     

Salbutamol***** Inh. 100:g

                                     

Candesartan (4 mg)

                                     

Celecoxib (200 mg)

                                     

Orlistat (120 mg)

                                     

Sildenafil (50 mg)

                                     

Olanzapine (10 mg)

                                     

Levofloxacin (500 mg)

                                     

Atorvastatin (10 mg)

                                     

Montelukast (10 mg)

                                     

Esomeprazol (20 mg)

                                     

Fluconazole (50 mg)

                                     

Zidovudine (300 mg)

                                     

Nevirapine (200 mg)

                                     

Azithromycin (500 mg)

                                     

Didanosine (ddI) (150 mg)

                                     

Indinavir (200 mg)

                                     

Lamivudine (150 mg)

                                     

Ofloxacin (200 mg)

                                     

Lamivudine + Zidovudine (150 mg+ 300 mg)

                                     

Zidovudine + Lamivudine + Abacavir (300 mg + 150 mg + 300 mg) #

                                     

* If not indicated, pharmaceutical dosage forms are tablets.
** stearate/ethylsuccinate
*** HCl
**** 50 mg (if 25 mg not available)
***** As sulphate
# If available as a fixed-dose combination.

Table K: Annual quantity sold per standard dose of original brand in public system: Volume of prescriptions

 

1998

1999

2000

2001

2002

2003

Product

           

Erythromycin

           

Ciprofloxacin

           

Rifampicin

           

Doxycycline

           

Cyclophosphamide

           

Hydrochlorothiazide

           

Atenolol

           

Salbutamol

           

Candesartan

           

Celecoxib

           

Orlistat

           

Sildenafil

           

Olanzapine

           

Levofloxacin

           

Atorvastatin

           

Montelukast

           

Esomeprazol

           

Fluconazole

           

Zidovudine

           

Nevirapine

           

Azithromycin

           

Didanosine (ddI)

           

Indinavir

           

Lamivudine

           

Ofloxacin

           

Lamivudine + Zidovudine

           

Zidovudine + Lamivudine + Abacavir

           

Table L: Annual quantity sold per standard dose of original brand in private system: volume of prescriptions

 

1998

1999

2000

2001

2002

2003

Product

           

Erythromycin

           

Ciprofloxacin

           

Rifampicin

           

Doxycycline

           

Cyclophosphamide

           

Hydrochlorothiazide

           

Atenolol

           

Salbutamol

           

Candesartan

           

Celecoxib

           

Orlistat

           

Sildenafil

           

Olanzapine

           

Levofloxacin

           

Atorvastatin

           

Montelukast

           

Esomeprazol

           

Fluconazole

           

Zidovudine

           

Nevirapine

           

Azithromycin

           

Didanosine (ddI)

           

Indinavir

           

Lamivudine

           

Ofloxacin

           

Lamivudine + Zidovudine

           

Zidovudine + Lamivudine + Abacavir

           

Table M: Annual quantity sold per standard dose of generic equivalent in public system: Volume of prescriptions

 

1998

1999

2000

2001

2002

2003

Product

           

Erythromycin

           

Ciprofloxacin

           

Rifampicin

           

Doxycycline

           

Cyclophosphamide

           

Hydrochlorothiazide

           

Atenolol

           

Salbutamol

           

Candesartan

           

Celecoxib

           

Orlistat

           

Sildenafil

           

Olanzapine

           

Levofloxacin

           

Atorvastatin

           

Montelukast

           

Esomeprazol

           

Fluconazole

           

Zidovudine

           

Nevirapine

           

Azithromycin

           

Didanosine (ddI)

           

Indinavir

           

Lamivudine

           

Ofloxacin

           

Lamivudine + Zidovudine

           

Zidovudine + Lamivudine + Abacavir

           

Table N: Annual quantity sold per standard dose of generic equivalent in private system: Volume of prescriptions

 

1998

1999

2000

2001

2002

2003

Product

           

Erythromycin

           

Ciprofloxacin

           

Rifampicin

           

Doxycycline

           

Cyclophosphamide

           

Hydrochlorothiazide

           

Atenolol

           

Salbutamol

           

Candesartan

           

Celecoxib

           

Orlistat

           

Sildenafil

           

Olanzapine

           

Levofloxacin

           

Atorvastatin

           

Montelukast

           

Esomeprazol

           

Fluconazole

           

Zidovudine

           

Nevirapine

           

Azithromycin

           

Didanosine (ddI)

           

Indinavir

           

Lamivudine

           

Ofloxacin

           

Lamivudine + Zidovudine

           

Zidovudine + Lamivudine + Abacavir

           
to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014